Calicheamicin Antibody-Drug Conjugates and Beyond

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 2, Issue , 2011, Pages 395-410

  Sapra, Puja ^b   Dijoseph, John ^a   Gerber, Hans Peter ^b  

^a Pfizer Research   (United States)

^b NONE

Author keywords

Calicheamicin; Cancer; Chemotherapy; Conjugate; Drug; Monoclonal antibody

Indexed keywords

EID: 84877585368     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch14     Document Type: Chapter

References (60)

1. Bernstein, I.D. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14, 474-475.
2. Voutsadakis, I.A. (2002) Gemtuzumab ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anti-Cancer Drugs, 13, 685-692.
3. DiJoseph, J.F., Dougher, M.M., Evans, D.Y., Zhou, B.B., and Damle, N.K. (2010) Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother. Pharmacol., 67, 741-749.
4. Zein, N., Sinha, A.M., McGahren, W.J., and Ellestad, G.A. (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, 1198-1201.
5. Damle, N.K. (2004) Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin. Biol. Ther., 4, 1445-1452.
6. Damle, N.K. and Frost, P. (2003) Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr. Opin. Pharmacol., 3, 386-390.
7. Dedon, P.C., and Goldberg, I.H. (1992) Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chem. Res. Toxicol., 5, 311-332.
8. Thorson, J.S. et al. (2000) Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharm. Des., 6, 1841-1879.
9. Gupta, P.B., Chaffer, C.L., and Weinberg, R.A. (2009) Cancer stem cells: mirage or reality? Nat. Med., 15, 1010-1012.
10. Zein, N., Poncin, M., Nilakantan, R., and Ellestad, G.A. (1989) Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science, 244, 697-699.
11. Greenstein, M., Wildey, M.J., and Maiese, W.M. (1995) The biochemical induction assay and its application in the detection of calicheamicins in Enediyne Antibiotics as Antitumor Agents (eds D.B. Borders and T.W. Doyle), Dekker, New York, pp. 29-47.
12. Hamann, P.R. et al. (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem., 13, 40-46.
13. Walker, S., Landovitz, R., Ding, W.D., Ellestad, G.A., and Kahne, D. (1992) Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc. Natl. Acad. Sci. USA, 89, 4608-4612.
14. Ikemoto, N. et al. (1995) Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc. Natl. Acad. Sci. USA, 92, 10506-10510.
15. Ellestad, G.A. (2006) From natural products to bioorganic chemistry. What's next?. J. Med. Chem., 49, 6627-6634.
16. Senter, P.D. (2009) Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol., 13, 235-244.
17. Lee, M.D. et al. (1989) Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J. Antibiot., 42, 1070-1087.
18. Hamann, P.R. et al. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem., 13, 47-58.
19. Crocker, P.R., and Zhang, J. (2002) New I-type lectins of the CD33-related siglec subgroup identified through genomics. Biochem. Soc. Symp., 83-94.
20. Vitale, C. et al. (2001) Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc. Natl. Acad. Sci. USA, 98, 5764-5769.
21. Griffin, J.D., Linch, D., Sabbath, K., Larcom, P., and Schlossman, S.F. (1984) A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res., 8, 521-534.
22. Legrand, O. et al. (2000) The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood, 96, 870-877.
23. Bernstein, I.D. et al. (1987) Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J. Clin. Invest., 79, 1153-1159.
24. Bernstein, I.D. et al. (1992) Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood, 79, 1811-1816.
25. Clarkson, B.D., and Berman, E. (1990) Clinical trials of chemotheraphy and bone marrow transplantation in acute myelogenous leukemia in Acute Myelogenous Leukemia: Progress and Controversies (ed. R.P. Gale), Wiley-Liss, New York, pp. 239-272.
26. Rowe, J.M. et al. (1990) Clinical trials modules with acute myelogenous leukemia: the ECOG experience in Acute Myelogenous Leukemia: Progress and Controversies (ed. R.P. Gale), Wiley-Liss, New York, pp. 87-115.
27. Vogler, W.R. et al. (1990) New approaches in the treatment of acute myeloblastic leukemia: results of recent Southeastern Study Group trials in Acute Myelogenous Leukemia: Progress and Controversies (ed. R.P. Gale), Wiley-Liss, New York, pp. 303-312.
28. Scheinberg, D.A. et al. (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol., 9, 478-490.
29. Larson, R.A. et al. (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 16, 1627-1636.
30. Sievers, E.L. et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol., 19, 3244-3254.
31. Giles, F.J. et al. (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413.
32. Rajvanshi, P., Shulman, H.M., Sievers, E.L., and McDonald, G.B. (2002) Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99, 2310-2314.
33. Boue, D.R., and Lebien, T.W. (1988) Structural characterization of the human B lymphocyte-restricted differentiation antigen CD22. Comparison with CD21 (complement receptor type 2/Epstein-Barr virus receptor). J. Immunol., 140, 192-199.
34. Bofill, M. et al. (1985) Human B cell development. II. Subpopulations in the human fetus. J. Immunol., 134, 1531-1538.
35. Schwartz-Albiez, R., Dorken, B., Monner, D.A., and Moldenhauer, G. (1991) CD22 antigen: biosynthesis, glycosylation and surface expression of a B lymphocyte protein involved in B cell activation and adhesion. Int. Immunol., 3, 623-633.
36. Dorken, B. et al. (1986) HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J. Immunol., 136, 4470-4479.
37. Crocker, P.R., and Varki, A. (2001) Siglecs, sialic acids and innate immunity. Trends Immunol., 22, 337-342.
38. Doody, G.M. et al. (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science, 269, 242-244.
39. Nitschke, L., Carsetti, R., Ocker, B., Kohler, G., and Lamers, M.C. (1997) CD22 is a negative regulator of B-cell receptor signalling. Curr. Biol., 7, 133-143.
40. Nitschke, L., Floyd, H., and Crocker, P.R. (2001) New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs. Scand. J. Immunol., 53, 227-234.
41. Tedder, T.F., Tuscano, J., Sato, S., and Kehrl, J.H. (1997) CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol., 15, 481-504.
42. Hanna, R., Ong, G.L., and Mattes, M.J. (1996) Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res., 56, 3062-3068.
43. Shan, D., and Press, O.W. (1995) Constitutive endocytosis and degradation of CD22 by human B cells. J. Immunol., 154, 4466-4475.
44. Vaickus, L., Ball, E.D., and Foon, K.A. (1991) Immune markers in hematologic malignancies. Crit. Rev. Oncol. Hematol., 11, 267-297.
45. Amercian Cancer Society (2006) Cancer Facts and Figures 2006, American Cancer Society, Atlanta, GA.
46. DiJoseph, J.F. et al. (2005) Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol. Immunother., 54, 11-24.
47. DiJoseph, J.F. et al. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103, 1807-1814.
48. DiJoseph, J.F. et al. (2004) Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res., 10, 8620-8629.
49. DiJoseph, J.F. et al. (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer Res., 12, 242-249.
50. Oflazoglu, E., Kissler, K.M., Sievers, E.L., Grewal, I.S., and Gerber, H.P. (2008) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br. J. Haematol. 142, 69-73.
51. DiJoseph, J.F., Dougher, M.M., Armellino, D.C., Evans, D.Y., and Damle, N.K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia, 21, 2240-2245.
52. Advani, A. et al. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol., 28, 2085-2093.
53. Krop, I.E. et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol., 28, 2698-2704.
54. Gerber, H.P. (2010) Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem. Pharmacol., 79, 1544-1552.
55. Carter, P.J., and Senter, P.D. (2008) Antibody-drug conjugates for cancer therapy. Cancer J., 14, 154-169.
56. Rybak, J.N., Trachsel, E., Scheuermann, J., and Neri, D. (2007) Ligand-based vascular targeting of disease. ChemMedChem, 2, 22-40.
57. Scott, A.M. et al. (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad. Sci. USA, 104, 4071-4076.
58. Stohrer, M., Boucher, Y., Stangassinger, M., and Jain, R.K. (2000) Oncotic pressure in solid tumors is elevated. Cancer Res., 60, 4251-4255.
59. Weinstein, J.N., and van Osdol, W. (1992) The macroscopic and microscopic pharmacology of monoclonal antibodies. Int. J. Immunopharmacol., 14, 457-463.
60. Junutula, J.R. et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol., 26, 925-932.